Venous thromboembolism in patients receiving neoadjuvant chemotherapy for advanced ovarian cancer and impact on survival
Deep Venous Thrombosis (DVT) is a common side effect of medical treatment and may be fatal due to pulmonary embolism. Many women who undertake therapy for ovarian cancer will have DVT.
This retrospective survey looked at the incidence of DVT for women who received neoadjuvant chemotherapy prior to surgery, for ovarian cancer. 286 women were included in the study from Canada. Overall survival was recorded and compared with those patients who did not have DVT.
During the neoadjuvant chemo almost 14% of these women had DVT. They had worse outcomes, with the mean overall survival being reduced by 45% to 15 months. It is noted that patients who had DVT often had lower serum albumen levels and were more likely to not proceed to surgery.
No comments:
Post a Comment